Fresenius SE & Co. KGaA

Earnings Release • Apr 22, 2013

Factsheet FY / 2012

COMPANY PROFILE

Fresenius is a health care group providing products and services for dialysis, hospitals and the medical care of patients at home. In addition, Fresenius focuses on hospital operation, as well as on engineering and services for hospitals and other health care facilities. Approximately 170,000 employees have dedicated themselves to the service of health in about 100 countries worldwide.

FRESENIUS GROUP IN FIGURES

€ in millions	2012	2011	2010	2009
Sales and Earnings
Sales 1	19,290	16,361	15,972	14,164
EBIT 2	3,075	2,563	2,418	2,054
Net income (before special items) 3	938	770	660	514
Earnings per ord. share in € (before special items) 3	5.42	4.73	4.08	3.18
Balance sheet and cash fl ow
Total assets	30,664	26,321	23,577	20,882
Non-current assets	22,551	19,170	17,142	15,519
Equity 4	12,758	10,577	8,844	7,491
Equity ratio 4	42%	40%	38%	36%
Net debt / EBITDA 5	2.6	2.8	2.6	3.0
Investments 6	4,179	2,395	1,402	931
Operating cash fl ow	2,438	1,689	1,911	1,553
Operating cash fl ow in % of sales	12.6%	10.3%	12.0%	11.0%
Profi tability
EBIT margin 2	15.9%	15.7%	15.1%	14.5%
Return on equity after taxes (ROE) 3	12.3%	12.9%	13.3%	12.1%
Return on operating assets (ROOA) 2	11.0%	10.9%	11.6%	10.5%
Return on invested capital (ROIC) 2	9.0%	8.8%	8.9%	8.2%
Employees (December 31)	169,324	149,351	137,552	130,510

1 2011 sales were adjusted by - € 161 million according to a U.S. GAAP accounting change. This solely relates to Fresenius Medical Care North America.

2 2012 adjusted for one-time costs (€ 6 million) related to the offer to the shareholders of RHÖN-

KLINIKUM AG as well as for other one-time costs (€ 86 million) at Fresenius Medical Care. 3 Net income attributable to shareholders of Fresenius SE & Co. KGaA, 2012 adjusted for a non-taxable investment gain (€ 34 million) and other one-time costs (€ 17 million) at Fresenius Medical Care as well as for one-time costs (€ 29 million) related to the offer to the shareholders of RHÖN-KLINIKUM AG. ²⁰⁰⁹– 2011 adjusted for the effects of mark-to-market accounting of the MEB and the CVR. 4

Including noncontrolling interest 5 2012 before special items

6 Investments in property, plant and equipment and intangible assets, acquisitions

GROUP STRUCTURE

The operating business comprises the four business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, all of which are legally independent entities managed by the operating parent company Fresenius SE & Co. KGaA.

BUSINESS SEGMENTS

			2012		2011
€ in millions		Sales	EBIT	Sales	EBIT
		10,741	1,813	9,031 1	1,491
		4,539	934	3,964	803
		3,200	322	2,665	270
		846	51	737	44

1 2011 sales were adjusted by - € 161 million according to a U.S. GAAP accounting change. This solely relates to Fresenius Medical Care North America.

• ▶ Fresenius Medical Care is the world's leading provider of services and products for patients with chronic kidney failure. As of December 31, 2012, Fresenius Medical Care was treating 257,916 patients in 3,160 dialysis clinics.
• ▶ Fresenius Kabi offers infusion therapies, intravenously administered generic drugs and clinical nutrition for seriously and chronically ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products in Germany.
• ▶ Fresenius Helios is one of the largest private hospital operators in Germany. HELIOS owns 72 hospitals, including 6 maximum care hospitals in Berlin-Buch, Duisburg, Erfurt, Krefeld, Schwerin and Wuppertal. HELIOS treats more than 2.9 million patients per year, thereof more than 770,000 inpatients, and operates more than 23,000 beds.
• ▶ Fresenius Vamed offers engineering and services for hospitals and other health care facilities.

SALES BY BUSINESS SEGMENT

2012: €19.3 billion

FRESENIUS SHARE / ADR

	Ordinary share
Securities code no.	578 560
ISIN	DE0005785604

Issuer	ISIN	in million	Coupon	rity
Fresenius Finance B. V.	XS0759200321	€500	4.25%	2019
Fresenius Finance B. V.	XS0873432511	€500	2.875%	2020
Fresenius US Finance II, Inc.	USU31436AD72	US\$500	9.00%	2015
Fresenius US Finance II, Inc.	XS0390398344	€275	8.75%	2015

Bonds of Fresenius Medical Care can be found under www.fmc-ag.com\Credit Relations.

FRESENIUS GROUP'S SENIOR NOTES

RELATIVE SHARE PRICE PERFORMANCE FRESENIUS SHARE VS. DAX DAX Fresenius ordinary share

SHARE PERFORMANCE 1

Volume

Matu-

1 month	- 2.0 %
4 th quarter	- 5.6 %
1 year	+ 21.6 %
5 years	+ 55.5 %
10 years	+ 624.8 %

Effective date / closing price: December 31, 2012

DEVELOPMENT ORDINARY SHARE DIVIDENDS IN €

Ticker symbol FRE ADR CUSIP 35804M105 ADR Ticker symbol FSNUY Number of ordinary shares (December 31, 2012) 178,188,260 Market capitalization (December 31, 2012) €15.5 billion

1 Proposal

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fl uctuations, uncertainties in litigation or investigative proceedings, and the availability of fi nancing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA

Registered Offi ce: Bad Homburg, Germany Commercial Register: Amtsgericht Bad Homburg, HRB 11852 Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE

Registered Offi ce: Bad Homburg, Germany

Commercial Register: Amtsgericht Bad Homburg, HRB 11673 Management Board: Dr. Ulf M. Schneider (Chairman), Mats Henriksson, Dr. Francesco De Meo, Dr. Jürgen Götz, Rice Powell, Stephan Sturm, Dr. Ernst Wastler

Chairman of the Supervisory Board: Dr. Gerd Krick

GROUP OUTLOOK 2013

	Targets 2013
Sales growth 1 (in constant currency)	7% – 10%
Net income 2 , growth (in constant currency)	7% – 12%
Capital expenditure	~ 5% of group sales

1 Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2013 adjusted for one-time integration costs of Fenwal, Inc. (~ € 50 million pre tax); 2012 adjusted for an investment gain and other one-time costs at Fresenius Medical Care as well as for one-time costs related to the offer to the shareholders of RHÖN-KLINIKUM AG.

For the outlook of the business segments please see the Investor News of February 26, 2013.

FINANCIAL CALENDAR

	Dates
Report on 1st quarter 2013	April 30, 2013
Annual General Meeting, Frankfurt / Main	May 17, 2013
Payment of dividend 1	May 20, 2013
Report on 1st half 2013	July 30, 2013
Report on 1st – 3rd quarter 2013	November 5, 2013

1 Subject to prior approval by the Annual General Meeting

CONTACT

Fresenius SE & Co. KGaA

Senior Vice President Telefax: ++49 61 72 6 08-24 88 Investor Relations e-mail: ir-fre@fresenius.com Else-Kröner-Straße 1 Internet: www.fresenius.de 61352 Bad Homburg v. d. H.

Birgit Grund Telephone: ++49 61 72 6 08-24 85